Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, outlines the changing landscape of kidney cancer, explaining the therapies at the forefront of the field right now. Dr Atkins highlights immuno-oncology combinations, mentioning a number of checkpoint inhibitors and VEGF inhibitors, including ipilimumab, nivolumab, atezolizumab, bevacizumab, cabozantinib, lenvatinib, everolimus, axitinib, avelumab, and sunitinib.
The agents at the forefront of kidney cancer treatment
